Gaining Control of Eosinophilic Disorders

Registration & Dinner @ 6:30 PM (EST) (Dinner provided).

Prefer to participate online? Register for our livestream at www.exchangecme.com/EGPAHESOrlandoStream

This program was developed by, or with financial support and influence from, Integritas Communications and is neither sponsored by nor endorsed by ATS.

There is no fee to attend this educational program; however, seating is limited. Preregistration does not guarantee seating. We recommend arriving at the symposium location early.

Program Description

Eosinophilic granulomatosis with polyangiitis (EGPA) and hypereosinophilic syndrome (HES) are both rare types of eosinophilic disorders. Diagnosis and management of these disorders is challenging due to their complex and overlapping pathologic features and heterogeneous systemic involvement. Both disorders carry substantial risks of morbidity and mortality due to delayed diagnosis and inadequate treatment. Interleukin (IL)-5 is a key driver of pathophysiology; therapies targeting IL-5 or the IL-5 receptor are a mainstay of treatment. In this confidence-based clinical decision CALIBRATE symposium, Drs. Praveen Akuthota, Philip Seo, and Michael Wechsler will discuss EGPA and HES patient cases with real-world, point-of-care decision checkpoints paired with confidence ratings to improve diagnosis and treatment sequencing.

Target Audience

This program is designed to educate pulmonologists, rheumatologists, clinical immunologists/allergists, hematologists, and other specialists who identify and manage patients with hypereosinophilic syndrome (HES) or eosinophilic granulomatosis with polyangiitis (EGPA).

Educational Objectives

After completing this activity, the participant should be better able to:

• Discuss the burdens of EGPA and HES with a focus on the effects of delayed diagnosis and suboptimal treatment
• Diagnose EGPA or HES promptly based on symptomology, red flags, medical history, ancillary testing, and appropriate multidisciplinary collaboration
• Describe the mechanistic rationale and trial evidence for biologic therapies for patients with EGPA or HES
• Construct biologic-based treatment regimens for EGPA or HES that optimize disease control, minimize corticosteroid use, and target long-term remission

Program Agenda

6:30 PM Registration and Dinner 

7:00 PM Preactivity Questionnaire and Faculty Introductions

7:10 PM Case-Based Examination of Pulmonary Recognition and Workup Decisions (HES Pathway)

7:45 PM Case-Based Examination of Pulmonary Recognition and Treatment Sequencing Decisions (EGPA Pathway)

8:15 PM Closing Remarks: Confidence Recalibration + Actionable Takeaways

8:20 PM Postactivity Questionnaire, and Q&A Session

Physician Accreditation Statement

Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

Integritas designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Integritas Contact Information

For more information about the approval of this program, please contact Integritas at info@exchangecme.com.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must attend the live symposium/live stream and complete the posttest and program evaluation. 

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Americans With Disabilities Act

Any activity registrant who feels s/he may need accommodation based on the impact of a disability should contact Integritas at info@exchangecme.com to discuss their specific needs.